Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation by Chafekar, Sidhartha M. et al.
DOI: 10.1002/cbic.200700338
Branched KLVFF Tetramers Strongly Potentiate
Inhibition of b-Amyloid Aggregation
Sidhartha M. Chafekar,[a] Hinke Malda,[b] Maarten Merkx,[b] E. W. Meijer,[b]
David Viertl,[c] Hilal A. Lashuel,[c] Frank Baas,[a, d] and Wiep Scheper*[a, d]
Introduction
One of the most prominent neuropathological hallmarks in the
brains of Alzheimer’s disease (AD) patients is the deposition of
senile plaques. These plaques are extracellular lesions that are
primarily composed of b-amyloid (Ab). Ab is a 40- or 42-amino-
acid peptide that is derived from the amyloid precursor pro-
tein (APP) by proteolytic processing. Genetic and neuropatho-
logical studies provide strong evidence for a central role of Ab
in the pathogenesis of AD.[1–4]
Ab is a highly fibrillogenic peptide that is prone to aggre-
gate into 6 to 10 nm diameter fibrils with the characteristic
cross-b structure.[5–7] Initial studies have shown that the aggre-
gation of Ab into fibrils is a prerequisite for its toxicity.[8–10]
Later studies demonstrated the neurotoxicity of different prefi-
brillar intermediates in the Ab aggregation pathway.[11–17] These
different aggregation states might mediate different toxic ef-
fects at different stages of the disease.[18] Protofibrils (PF)[19] for
example, are intermediates on the pathway towards mature fi-
brils. PF are short (10–200 nm) soluble curvilinear structures
that have several characteristics of mature fibrils (high b-sheet
content, and a fibril-like structure). Like fibrils, PFs have also
been shown to induce neurotoxicity in culture, and acute elec-
trophysiological changes.[11] The exact nature of the Ab species
that causes toxicity and eventually neurodegeneration in vivo
is not known, but these studies do indicate that Ab must be in
an aggregated state to be toxic. This suggests that the preven-
tion of Ab aggregation might inhibit Ab neurotoxicity.
Previous studies on the aggregation process of Ab identified
the critical region that is involved in amyloid fibril forma-
tion.[20,21] The hydrophobic core at residues 16–20 of Ab, KLVFF,
are crucial for the formation of b-sheet structures by Ab. It was
also shown that KLVFF binds to the homologous sequence in
Ab and prevents its aggregation into amyloid fibrils.[22,23] This
KLVFF sequence has served as a lead compound for the devel-
opment of inhibitory agents that are aimed at preventing Ab
aggregation in vivo.[24,25] KLVFF has also been shown to reduce
amyloid deposits in vivo.[26]
The use of multiple simultaneous interactions to enhance
the affinity and specificity of binding, known as multivalency, is
an important concept in biology. In the past, different types of
scaffold molecules have been used to obtain multivalent struc-
tures, such as colloidal gold particles[13] and poly(ethylene
glycol) (PEG).[25] A disadvantage of these approaches is the
large size of the particles (PEG) and the lack of control over
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the number of peptides attached (colloidal gold). These dis-
ACHTUNGTRENNUNGadvantages are circumvented when using denACHTUNGTRENNUNGdri ACHTUNGTRENNUNGmers. Den-
drimers are multivalent macromolecules with regular, highly
branched structures and dimensions that resemble those of
small proteins; they have been used in several different biolog-
ical applications.[27] In this study we have synthesized a first-
generation KLVFF dendrimer by using native chemical liga-
tion,[28] thereby generating a small, well-defined molecule that
is capable of making multivalent interactions. We have investi-
gated the effect of dendritic KLVFF on the aggregation of low
molecular weight (LMW) Ab1–42 as well as its effects on pre-
formed aggregates.
Our data show that the coupling of KLVFF to a dendrimeric
scaffold potentiates its inhibitory effect on Ab1–42 aggregation
as well as on the disassembly of pre-existing aggregates. Thus,
our studies indicate that a dendrimer that contains multiple
copies of KLVFF might have therapeutic potential in Alzheim-
er’s disease.
Results
Synthesis and characterization of fibrillogenesis inhibitor
compounds
The peptide–dendrimer complexes in this study were synthe-
sized by using native chemical ligation. Four equivalents of the
MPAL thioester of KLVFFGG (K1) were ligated to one equivalent
of the cysteine dendrimer C4 (see the dotted box in Scheme 1);
this resulted in the formation of the [KLVFFFGG]4 dendrimer
(K4). The chemical structures of K1 and K4 are shown in
Scheme 1. The identity and purity of the peptides were verified
by MALDI-TOF (see Figure S1)
Aggregation properties of the KLVFF compounds
Before assessing the performance of K1 and K4 as inhbitors of
Ab1–42 aggregation, we first studied the possible self-aggrega-
tion of these KLVFF peptides. Neither K1 nor K4 showed Thiofla-
vin T (ThT) binding after incubation for 24 h at 37 8C. (Fig-
ure 1A). Increasing the aggregation time of either compound
up to 5 days did not lead to an increase in ThT fluorescence
(not shown). Morphological analysis by AFM showed the ab-
sence of fibrillar aggregates in the K4 sample; this confirms the
results from the ThT assay (Figure 1B). Only globular structures,
with a diameter of 20–80 nm and height of 10–15 nm were
ACHTUNGTRENNUNGobserved after aggregation at 37 8C for 24 h (Figure 1B). These
data indicate that the dendritic KLVFF compound does not
form fibrils or other structures with high b-sheet content.
Dendritic KLVFF is a more potent inhibitor of LMW Ab
ACHTUNGTRENNUNGaggregation than monomeric KLVFF
LMW Ab was prepared as described in the Experimental Sec-
tion. Electron microscopy (EM) analysis showed, as expected
for LMW Ab, only very few oligomer-like structures at t=0 (Fig-
ure 2B, upper left). LMW Ab1–42 was aggregated for 24 h in the
presence of K1 or K4 in different ratios. In order to directly com-
pare the effects of K1 and K4 on Ab aggregation, the ratios are
expressed per mole of KLVFF
peptide subunit. ThT analysis
showed that K4 inhibits Ab1–42
aggregation in a concentration-
dependent manner; the stron-
gest inhibition occurred at the
highest concentration used (Fig-
ure 2A). A 1:4 ratio of Ab/K (in
K4) inhibits the relative change
of ThT fluorescence (Rel.DThT)
by more than 90%, whereas the
same ratio of K1 inhibits
Rel.DThT by only 25%. More-
over, a much lower ratio of 1:0.2
for K4 also resulted in an inhibi-
tion of 25%; this indicates that
K4 inhibits Ab1–42 aggregation to
the same extent as K1 at a 20-
fold lower concentration of the
peptide subunit (and at 80-fold
lower concentration per conju-
gate molecule). K4 is thus a
much more potent inhibitor of
Ab1–42 aggregation than K1. Half-
maximal inhibition of LMW Ab
aggregation in assays that were
performed both at 20 mm and
10 mm occurs at a comparable
Scheme 1. Chemical structures of the interfering peptides. Chemical structures of monomeric KLVFFGG (K1) and
dendritic KLVFFGG (K4). The dotted box shows the structure of the cystein dendrimer (C4).
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Ab/K (K4) ratio of approximately 1:0.5, which corresponds to a
concentration of 10 mm Ab and 1.25 mm K4.
EM analysis was performed to study the morphology of the
aggregates that form in the presence and absence of K1 and
K4. Aggregation of LMW Ab1–42 in the absence of inhibitors
showed the formation of fibrillar structures (Figure 2B, upper
right). When LMW Ab1–42 aggregation is strongly inhibited
ACHTUNGTRENNUNG(>90%) by K4 (Ab/K=1:4), only small nonfibrillar structures are
detected (Figure 2B, lower right), but when the same ratio for
K1, which only results in 25% aggregation inhibition, was used,
fibrillar structures were still observed (Figure 2B, compare
lower left to lower right). EM analysis thus confirmed the re-
sults of the ThT assay.
To show that the effect of K4 on Ab1–42 aggregation is specifi-
cally caused by the KLVFF sequence, a similar co-aggregation
experiment was performed on LMW Ab1–42 with a dendrimer
that contained four peptides, each with five non-Ab-related
amino acids (GRGDS) with a GG spacer (G4). G4 had no inhibito-
ry effect on Ab1–42 aggregation even at the highest ratio used
(1:4). This result shows that the effect caused by K4 is mediated
by the Ab-derived sequence KLVFF.
Dendritic KLVFF disassembles mature Ab1–42 fibrils
To test whether the KLVFF derivatives can also cause the disas-
sembly of mature Ab1–42 fibrils (fAb), fAb was incubated with
K1 and K4 for 24 hours in different ratios. Figure 3A shows that
K4 disassembles fAb in a concentration-dependent manner. A
significant effect of K4 on fibril disassembly of 20% was already
observed at an Ab/K ratio of 1:0.2. Increasing the concentration
of K4 up to an Ab/K ratio of 1:16 increased the disassembly to
65%. An Ab/K (in K1) ratio of 1:16 caused a fibril breakdown of
only 25%. Thus, K4 breaks down the preformed Ab1–42 fibrils
much more potently. Disassembly of mature fibrils by 50% by
K4 is observed at an Ab/K ratio of 1:2.7; this corresponds to
concentrations of 10 mm Ab and 6.75 mm K4. The specificity of
the effect of K4 was again shown by the small effect that the
G4 dendrimer had on fibril disassembly (10% at an Ab/G (in G4)
ratio of 1:16). As an additional control for the specificity of the
effect of K4, we also studied the
effect of the dendrimer itself
(C4), because previous studies
have shown that dendritic struc-
tures are capable of breaking
down preformed fibrillar aggre-
gates by themselves. C4 reduced
ThT binding only by 10% at an
Ab/C4 ratio of 1:16. This indicates
that the observed effect by K4 is
sequence specific. EM analysis of
fibrillar Ab preparations, con-
firmed the fibrillar nature of the
starting material (Figure 3B,
upper left). EM analysis of the
Ab/K1 co-aggregate (Ab/K-ratio
1:16) shows many fibrillar struc-
tures; this confirms that K1 has
only a minor effect on fibril disassembly (Figure 3B, upper
right). In contrast, at the same Ab/K (in K4) ratio no fibrillar
structures were detected. Instead, globular, more oligomer-like
structures were observed (Figure 3B, lower left). The starting
level of ThT binding was only 35%, which indicates that fewer
fibrillar structures might be have been present. With Ab/G4 co-
aggregates no differences with Ab alone were observed (Fig-
ure 3B, lower right). Together these results show the increased
potency of K4 on fibril disassembly compared to K1.
Purification and characterization of protofibrillar Ab1–42
To study the effect of the inhibitory agents on preformed pro-
tofibrils (PF), we prepared highly enriched PF Ab aggregates as
described in the Experimental Section. The PF fraction was sep-
arated from the LMW forms of Ab1–42 by size-exclusion chroma-
tography (SEC), which showed two separate peaks in the chro-
matogram (Figure 4A).
To study the kinetics of Ab1–42 aggregation, PF and LMW
Ab1–42 preparations were aggregated for 24 h at 37 8C. LMW
Ab1–42 shows little ThT fluorescence at t=0. In contrast, PF Ab1–
42 had a fivefold higher ThT fluorescence; this indicates that PF
Ab1–42 contains more b sheets than LMW Ab1–42 at t=0. After
24 h of aggregation, LMW Ab1–42 and PF Ab1–42 both reached a
similar level of ThT fluorescence (Figure 4B). To confirm the
structure of the PF preparation, EM analysis was performed.
Short curvilinear structures, which are characteristic for protofi-
brils, were observed (Figure 4C, left). Incubation of protofibrils
for 24 h at 37 8C resulted in the formation of fibrils (Figure 4B,
right) ; this confirmed that protofibrils are intermediates on the
pathway to fibrils.
Dendritic KLVFF interferes in protofibril-to-fibril conversion
by disassembling protofibrils
To study the effect of the K4 peptide dendrimer on PF aggre-
gates, SEC-purified PF Ab1–42 was aggregated for 24 h in pres-
ence or absence of K1 and K4 in different ratios. ThT analysis
showed that K4 interferes in the protofibril-to-fibril conversion
Figure 1. KLVFF derivatives do not self aggregate. A) KLVFF derivatives were aggregated for 24 h at 37 8C and the
b-sheet content was measured by using a ThT assay. Shown is a representative graph of a ThT assay of the K1/K4
peptides aggregated at t=0 and 24 h. B) The morphology of the novel dendritic KLVFF was analyzed by AFM. A
representative AFM micrograph (image size is 2000I2000 nm) at t=24 h is shown.
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of Ab1–42 in a concentration-dependent manner (Figure 5A). A
1:1 ratio of Ab/K (in K4) limits the relative change of the ThT
fluorescence (Rel.DThT) to only 35% of the normally observed
increase. At Ab/K (in K4) ratios of 1:2 and higher the Rel.DThT
of Ab1–42 after 24 h is actually decreased; this indicates the dis-
assembly of pre-existing PF. Increasing the K4 concentration up
to an Ab/K ratio of 1:16 caused further disassembly of PF of up
to 70%. A 1:8 ratio of Ab/K (in K1) limits the conversion of PF
to fibril to 55%, whereas the same ratio of Ab/K (in K4) results
in the breakdown of the pre-existing PF by 55%. EM analysis
of the morphology of the PF Ab/K4 co-aggregates shows the
absence of fibrils and disappearance of PF in the presence of
high concentrations of K4. Instead, a rearrangement
of PF Ab1–42 into amorphous aggregates (Figure 5B;
right) is observed. This corroborates the results from
the ThT assay because amorphous aggregates do not
show ThT fluorescence. In the presence of K1, fibrillar
structures were still observed (Figure 5B; left).
Discussion
One of the key pathogenic factors in AD is the Ab
peptide. Ab aggregates into fibrils via several inter-
mediate aggregation species. Different aggregated
species might exert different toxic effects,[18] for ex-
ample, our own previous work showed the induction
of endoplasmic reticulum stress with oligomeric, but
not with fibrillar Ab aggregates.[29] Nevertheless,
plaques in AD patients consist mainly of fibrillar Ab
aggregates. Fibrillar Ab has been shown to be toxic
in culture, and might also be responsible for the neu-
ronal loss that is observed in AD patients. In any
case, it is clear that aggregation of Ab is a prerequi-
site for toxicity, therefore the prevention of Ab aggre-
gation might inhibit Ab-induced neurotoxicity. To this
end, we investigated intervention in Ab1–42 aggrega-
tion by using a multivalent KLVFF variant. We suc-
cessfully produced a dendritic variant of KLVFF by
using native chemical ligation. Like the monomeric
K1, the dendritic K4 shows no self-aggregation, not
even after prolonged incubation at 37 8C, which is
important for downstream applications that require a
soluble agent.
In this study the effect of the branched KLVFF
structure (K4) was compared to the monomeric KLVFF
(K1). Because different Ab species are known to con-
tribute to AD pathogenesis, intervention of Ab aggre-
gation was studied at different aggregation stages of
Ab : the first onset of aggregation (LMW), the aggre-
gation of intermediate species (PF) and the aggregat-
ed mature fibrils (fAb). To prevent Ab from reaching
an aggregated state, we intervened at the first onset
of aggregation by starting from the LMW state. K4
was found to be highly effective in preventing LMW
Ab1–42 aggregation, and to be much more potent
than K1, as indicated by both the amount of fluores-
cence reduction at the same 1:4 ratio for K1 (30%)
and K4 (90%) as well as the 20-fold lower concentration of K4
(per peptide subunit) that was needed for a similar inhibition
as K1. Previously, a branched hexameric retro-inverso FFVLK
was shown to increase the potency of Ab1–40 aggregation in-
hibition.[25] The multivalent effect that is reported in this study
was threefold of a hexamer compared to a dimeric conjugate;
this indicates that the K4 conjugate from our study gives a
stronger multivalent effect. However, a direct comparison of
the data is difficult because another study showed that a
KLVFF analogue is a more potent inhibitor of Ab1–40 than of
Ab1–42 aggregation,
[30] and because vastly different Ab and con-
jugate concentrations were used.
Figure 2. K4 is a potent inhibitor of LMW Ab aggregation. A) LMW Ab was co-incubated
with K1, K4 and G4 in the indicated ratios for 24 h. The b-sheet content was analyzed by
the ThT assay. Shown is a graph of a ThT assay that was performed on the aggregates
(n=6–9 from 2–3 independent experiments; meanS.D.). The increase in ThT fluores-
cence, without inhibitors, was set to 100% (Rel.DThT). Inhibitory effects of the KLVFF
compounds on LMW Ab aggregation were all relative to this control. Ratios are ex-
pressed per KLVFF peptide subunit. B) The morphology of the (co-)aggregates was ana-
lyzed by EM. Shown are representative EM pictures of the co-aggregates of LMW Ab
without inhibitors at t=0 (upper left) and t=24 h (upper right) and at t=24 with K1
(lower left) or K4 (lower right). Ab to peptide ratios are indicated in the figure. Scale bar:
100 nm.
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Another possibility for aggregation intervention is the disas-
sembly of preformed fAb. Previous studies have shown that
KLVFF analogues are capable of disassembling preformed fi-
brils.[30, 31] Our study also shows that K4 disassembles fAb in a
concentration-dependent manner and in a more potent way
than K1; this was indicated by both the amount of ThT fluores-
cence reduction at the same 1:16 Ab/K ratio for K1 (25%) and
K4 (65%), as well as the 40-fold lower concentration of K4 (per
peptide subunit) that was needed to induce similar inhibition
to K1. It should be noted however, that even the highest con-
centration of K4 did not cause a complete breakdown of the fi-
brils ; about 35% of potentially toxic amyloid fibrils remained
in solution. This might be a drawback for the potential use of
K4 as a therapeutic agent in fibril breakdown. In contrast, the
previously reported hexameric PEG–FFVLK conjugate
was not capable of inducing fibril disassembly.[25] This
might be due to the use of the PEG scaffold, which is
relatively large (10 kDa) compared to the first genera-
tion dendrimer (729 Da).
Because PF are intermediate species on the path-
way to fibrillization, they are an excellent experimen-
tal model to study both aggregation inhibition and
the breakdown of pre-exisiting aggregates in one ex-
perimental setup. In addition, PF have been shown
to have diverse toxic effects in vitro.[11] An early onset
variant of AD, caused by the “Arctic” mutation in APP
is shown to result in accelerated production of PF;[32]
this indicates the relevance of PF for AD pathogene-
sis. We show that K4 also has a more potent inhibito-
ry effect than K1 for the aggregation from PF to fAb1–
42. This is best indicated by the fact that an Ab/K
ratio (for K1) of 1:8 results in inhibition of the PF-to-
fAb conversion by 55% whereas the same ratio for K4
results in PF breakdown of 55%. ThT analysis shows a
concentration-dependent effect of K4 on PF aggrega-
tion; lower concentrations inhibit the further aggre-
gation of fibrils, and higher K4 concentrations cause
increased PF disassembly. We also show that K4 rear-
ranges PF Ab1–42 into amorphous aggregates. This is
different from the disassembly of preformed fibrils
into globular more oligomer-like structures, and it
suggests that there is a different mechanism for the
disassembly of protofibrils by K4.
Our study shows that K4 is much more potent than
K1 and thus has a multivalent inhibitory effect on all
of the aggregation species that were studied. The
effect of K4 on the inhibition of LMW aggregation
compared to the breakdown of pre-formed fibrillar
aggregates, however, occurs with different kinetics as
indicated by the concentrations of K4 that are
needed for half-maximal inhibition. The half-maximal
inhibition for aggregation of 10 mm Ab is attained
with 1.25 mm K4. To reach half-maximal disassembly
of 10 mm fibrils, however, a more than fivefold higher
K4 concentration of 6.75 mm is required. This suggests
that K4 exerts its effect predominantly on LMW Ab.
Because fAb is in equilibrium with LMW species, this
suggests that the strong effect of K4 on LMW Ab will shift this
equilibrium between fAb and LMW towards the LMW state,
and thus cause a disassembly of existing fibrillar aggregates.
Previous studies have shown an inhibitory effect of nonfunc-
tionalized amine-terminated polyamine dendrimers on amyloid
formation by Ab1–28 and prion protein (PrP) fragments.
[33–36] Ab
aggregation was inhibited by third-generation amine-terminat-
ed polyamine dendrimers, and the inhibition increased with
ACHTUNGTRENNUNGincreasing dendrimer concentration and generation. To show
that the multivalent effect of K4 was specifically caused by the
KLVFF sequence and not by the dendritic structure itself, we
performed similar aggregation assays with a dendrimer that
consisted of 4 unrelated pentapeptides (G4). Co-incubation of
G4 and Ab1–42 caused only a small inhibition of LMW Ab1–42 ag-
Figure 3. K4 disassembles mature Ab fibrils more potently then K1. A) Fibrillar Ab was co-
incubated with different concentrations of K1, K4, G4 and C4 for 24 h. The b-sheet content
was analyzed by the ThT assay. Shown is a graph of a ThT assay that was performed on
the aggregates (n=6 from two independent experiments; mean S.D.). The ThT fluo-
rescence of fibrillar Ab without inhibitors was set to 100%. The inhibitory effect of the
compounds was compared to this control. Ratios are expressed per KLVFF peptide sub-
ACHTUNGTRENNUNGunit. B) The morphology of the (co-)aggregates was analyzed by EM. Shown are repre-
sentative EM pictures of (co-)aggregates of fibrillar Ab alone (upper left), in presence of
K1 (upper right), K4 (lower left) and G4 (lower right). Ab/peptide ratios are indicated in the
figure. Scale bar: 100 nm.
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gregation, and had no effect on fibril breakdown in any of the
Ab/G4 ratios that were studied. The cysteine-dendrimer (C4)
showed only a minor effect on fibril breakdown; this also sug-
gests that it is unlikely that the amine-terminated PPI dendri-
ACHTUNGTRENNUNGmers would have an effect on Ab aggregation. This result
clearly shows that the more potent effect of K4 on Ab1–42 ag-
gregation is sequence specific. The potency of a multivalent
KLVFF derivative might be enhanced by using a higher genera-
tion dendrimer, but this is likely to also enhance sequence-un-
specific effects, as observed with the third and higher genera-
tion amine-terminated polyamine dendrimers.[34,35] In addition,
with increasing generation, the hydrophobicity will increase, as
well as its size and shape, thereby loosing the advantage of a
soluble small-size inhibitor.
Although we can not fully exclude the possibility that the
strong inhibiton caused by K4 is caused by steric hindrance by
the attachment of any structure to KLVFF, the strongly in-
creased potency of K4 relative to K1 suggests a multivalent
effect. This multivalent effect might also apply for other potent
KLVFF-derived aggregation inhibitors. Delivery across the
blood–brain barrier (BBB) might be important for a therapeutic
agent for AD. However, a study in mice showed that a mono-
clonal antibody against Ab can still be effective when applied
in the periphery.[37] Injection of this antibody was shown to
produce a “sink” effect by drawing soluble Ab from the brain
into the bloodstream. This could then potentially halt or even
reverse plaque formation. Whether dendritic KLVFF can work in
a similar manner awaits further study. In addition, modifica-
tions can facilitate passage across the BBB. An analogue of the
KLVFF peptide that was protected against proteolytic degrada-
tion, and that had increased BBB permeability has been suc-
cessfully used in a rat model of brain amyloidosis.[26] It was
Figure 4. Purification and aggregation kinetics of PF Ab. A) Protofibrillar (PF)
Ab was prepared as described in the Experimental Section and was purified
by size exclusion chromatography (SEC) by using a calibrated Superdex 75
10/30 HR column. Size exclusion of the Ab preparation results in separation
of LMW Ab species from PF Ab. Shown is a representative size exclusion
chromatogram. B) LMW and PF fractions were aggregated for 24 h at 37 8C.
The b-sheet content was analyzed by the ThT assay at t=0 (*) and 24 h (*).
Shown is a representative graph from a ThT assay on PF and LMW Ab. The
bracket in the graph indicates the change in ThT fluorescence after 24 h
(DThT) C) The morphology of PF Ab before and after the aggregation was
studied by EM analysis. Shown are representative electron micrographs of
PF Ab at t=0 (left) and 24 h (right). Scale bar: 100 nm
Figure 5. K4 dissasembles protofibrillar Ab. A) Protofibrillar Ab was co-incu-
bated with different concentrations of K1 and K4 for 24 h and the b-sheet
content was analyzed by the ThT assay. Shown is a graph of a ThT assay that
was performed on the aggregates (n=5 from two independent experi-
ments; meanS.D.). The increase of ThT fluorescence without inhibitors,
was set to 100% (Rel.DThT). Ratios are expressed per KLVFF peptide subunit.
B) The morphology of the co-aggregates was analyzed by EM. Shown are
representative EM pictures of co-aggregates of PF Ab in the presence of K1
(left) or K4 (right). The Ab-to-peptide ratios are indicated in the figure. Scale
bar: 100 nm.
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shown to prevent Ab-induced spatial memory impairments,
and caused a partial reduction of amyloid deposits. Our data
suggest that dendritic derivatives of KLVFF might further in-
crease its efficacy. In addition, several small-molecule inhibitors
have also been shown to inhibit amyloid aggregation,[38] and
their efficacy might also be further increased via multivalent
display on dendrimers. Dendrimers might thus be a valuable
tool that can increase the therapeutic efficacy of many aggre-
gation inhibitors.
The small size and controlled synthesis of dendrimeric struc-
tures is a major advantage when creating multivalent mole-
cules. In this study, we have employed this advantage to
create a small, multivalent and sequence-specific inhibitor of
Ab aggregation. The effect of K4 on the inhibition of fibril for-
mation as well as fibril disassembly suggests that many of the
steps of Ab fibrillogenesis are reversible. Because K4 acts on all
different aggregation species, it has potential for use as a ther-
apeutic agent.
Experimental Section
Synthesis of peptide–dendrimer conjugate: In this study native
chemical ligation was used for the generation of peptide dendri-
ACHTUNGTRENNUNGmers.[28] Standard tert-butyloxycarbonyl (t-Boc)-mediated solid-
phase peptide synthesis was used to make the KLVFFGG peptide.
The two glycine residues (GG) were included to provide a spacer
between the KLVFF sequence and the dendrimer structure. The
KLVFFGG peptides were functionalized with a C-terminal mercapto-
propionic acid leucine (MPAL) thioester, as described in Hackeng
et al.[39] Functionalization of the amine-terminated poly(propylene
imine) dendrimers (kindly provided by DSM (Geleen, The Nether-
lands)) with cysteine residues, was done as described in van Baal
et al.[28]
Four equivalents of peptide thioester were ligated to one equiva-
lent of the cysteine dendrimer by using standard ligation condi-
tions (Tris buffer pH 7.5, 6m guanidine, 2% (v/v) thiophenol, 2%
ACHTUNGTRENNUNG(v/v) benzylmercaptan, 37 8C), with stirring for 1 h at 37 8C. This re-
sulted in the formation of [KLVFFGG]4 dendrimer. The ligation prod-
uct was further purified by using reversed-phase HPLC as de-
scribed in van Baal et al.[28] The cysteine dendrimer is referred to as
C4, KLVFFGG is referred to as K1 and the [KLVFFGG]4 dendrimer is
re ACHTUNGTRENNUNGferred to as K4. As an additional control in the aggregation ex-
periments, we used a dendrimer with 4 copies of the unrelated
pentapeptide GRGDS with GG as a spacer (G4).
[28] All peptides and
peptide dendrimers were analyzed by matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometry (MALDI-TOF MS)
analysis, by using a-cyano-4-hydrocinnamic acid as a matrix. The
MS data of the K1 and K4 structures are shown in the supplementa-
ry data. The MS data of G4 as well as C4 have been shown previ-
ously in van Baal et al.[28]
Preparation and purification of different Amyloid-b1–42 species :
Purified Ab1–42 peptide was purchased from California peptide
(Napa, CA, USA) or Anaspec (San Jose, CA, USA). For the prepara-
tion of protofibrils, Ab1–42 was initially diluted in DMSO, then in
water, and finally in Tris–HCl, pH 7.4, to give final concentrations of
5%, 25 mm and 1 mgmL1 (222 mm) for DMSO, Tris and Ab, respec-
tively. Large, insoluble particles (fibrils) were removed by a 5 min
centrifugation step at 13000 g at 4 8C. The supernatants were
loaded onto a Superdex 75 HR 10/30 gel-filtration column (GE
Healthcare Europe, Munich, Germany), and subsequently equilibrat-
ed with Tris–HCl (5 mm, pH 7.4), NaCl (75 mm) to separate PF from
LMW species. The column was calibrated by using the following
proteins as molecular mass standards: ribonuclease A (13.7 kDa),
chymotrypsinogen A (25 kDa), ovalbumin (43 kDa) and albumin
(67 kDa). The protein was eluted at a flow rate of 0.5 mLmin1 and
0.5 mL fractions were collected. To assess which eluted fractions
from the PF or LMW peaks had the highest Ab1–42 concentration, a
sample of each of the fractions was run on a 16.5% SDS gel and
proteins were visualized by silver staining. For each peak the most
intense bands on the gels (which contained the most of the Ab1–42
peptide) were pooled and the concentration of the final mixture
was determined by using a BCA protein assay (Pierce, Rockford, IL,
USA), before the co-aggregation experiments were initiated. EM
analysis was performed to confirm the protofibrillar structures.
To obtain LMW species, hexafluoroisopropanol (HFIP) was used as
an initial solvent. Ab1–42 was dissolved in HFIP at a final concentra-
tion of 1 mgmL1, aliquoted, and allowed to evaporate by using a
SpeedVac centrifuge. The resulting peptide film was stored at
80 8C until further use. For co-aggregation experiments the pep-
tide film was dissolved in DMSO, and sonicated in a bath sonicator
for 10 min. For LMW preparation, Ab1–42 was subsequently diluted
in 5 mm Tris–HCl, pH 7.4, 75 mm NaCl buffer to a final concentra-
tion of 20 mm. EM analysis was performed to confirm the absence
of fibrillar structures or other aggregates. This method has previ-
ously been shown to yield mainly monomeric and small soluble Ab
species.[16] HFIP-treated LMW Ab species were also analyzed by SEC
(not shown); they eluted from the column at approximately the
same time as the SEC-purified LMW Ab separated from protofibrils.
SEC-purified LMW Ab (not shown) as well as HFIP-treated Ab (Fig-
ure 2B) showed very few structures on EM. These findings con-
firmed that LMW species that were obtained by either method
were too small to be detected by EM as was previously report-
ed.[11,16,19] Both LMW species also showed very low ThT binding.
This indicated that they were similar structures. In addition, the
same co-aggregation assays as with HFIP-treated LMW Ab (at
20 mm, see below), were also performed with the SEC-purified
LMW Ab species at 10 mm (not shown) and showed similar results.
To obtain fibrillar Ab1–42 (fAb) 10 mm HCl was added to Ab/DMSO
under continuous vortexing to bring the peptide to a final concen-
tration of 100 mm followed by incubating at 37 8C for 24 h. The fi-
brillar Ab1–42 preparation was centrifuged (220000g) in a Beckman
tabletop ultracentrifuge for 30 min at room temperature and the
pellet was resuspended in 4% DMSO/10 mm HCl (pH 4). The rela-
tive concentration of the fibrillar Ab1–42 preparations was deter-
mined by a Bradford protein assay (Biorad, Hercules, CA, USA).
Co-aggregation assay: For the fibril disaggregation experiments,
the fibrillar samples were further diluted in 5 mm Tris–HCl, pH 7.4,
75 mm NaCl buffer to a final concentration of 10 mm prior to the
addition of K1 or K4. For the protofibril aggregation experiments,
isolated protofibril preparations were used at a final concentration
of 10 mm in 5 mm Tris–HCl, pH 7.4, 75 mm NaCl in the presence or
absence of the inhibitor peptides. Freshly prepared HFIP-treated
LMW Ab was used at a final concentration of 20 mm in the co-ag-
gregation assays. The samples were first incubated at 4 8C for 1 h
to allow binding of the aggregation inhibitors to Ab1–42. Subse-
quently, the samples were allowed to aggregate for 24 h at 37 8C.
After 24 h samples were taken to perform a Thioflavin T assay and
EM analysis.
Thioflavin T assay : A 100 mm aqueous solution of Thioflavin T
(ThT) was prepared and filtered through a 0.2 mm filter. The Ab ag-
gregates were diluted to a final concentration of 5 mm into gly-
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cine/NaOH (90 mm, pH 8.5) that contained 10 mm ThT. Fluorescence
was measured in 96-well plates by using a Fluostar microplate
reader (Fluostar Optima, BMG Labtech, Offenburg, Germany) at an
excitation wavelength of 450 nm and emission at 485 nm. In the
ThT graph of the co-aggregation experiments the relative change
in fluorescence (Rel.DThT in%) was plotted against the molar ratio
of Ab1–42/test sample. In order to directly compare the effects of K4
and K1 on Ab aggregation, the ratios were expressed per mole of
KLVFF peptide subunit, and not per mole of conjugate molecule.
The change in ThT fluorescence of LMW or PF Ab1–42 after 24 h of
aggregation in the absence of the interfering peptides was set at
100%. The other experimental conditions were all related to this
control. For the aggregation assays with fAb, the ThT fluorescence
of fibrils in the absence of interfering peptides was set at 100%.
Electron microscopy: Ab1–42 preparations were adsorbed onto
300-mesh formvar/copper grids for 5 min and the excess fluid was
filtered off. Subsequently, the samples were stained with 1%
uranyl acetate for 5 min, the excess fluid was removed and the
grids were analyzed with a Philips EM-420 or a Philips CM 100
transmission electron microscope operated at 100 kV.
Atomic force microscopy (AFM): A total of 10 mL of each sample
was adsorbed onto a freshly cleaved mica surface and was left to
dry at room temperature for 1 h. AFM images were obtained at
room temperature with a Nanoscope III (Digital Instruments, Santa
Barbara, CA) by using force–volume mode operating in liquid.
Measurements were performed with a constant retraction speed of
355 nms1. Calibrated standard triangular Si3N4 AFM cantilevers
from Veeco (Santa Barbara, CA) were used with a 0.06 Nm1 nomi-
nal spring constant.
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